FR2596758B1 - Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant - Google Patents

Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant

Info

Publication number
FR2596758B1
FR2596758B1 FR8704705A FR8704705A FR2596758B1 FR 2596758 B1 FR2596758 B1 FR 2596758B1 FR 8704705 A FR8704705 A FR 8704705A FR 8704705 A FR8704705 A FR 8704705A FR 2596758 B1 FR2596758 B1 FR 2596758B1
Authority
FR
France
Prior art keywords
amlodipine
compositions containing
improved
pharmaceutical
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8704705A
Other languages
English (en)
French (fr)
Other versions
FR2596758A1 (fr
Inventor
Edward Davison
James Ingram Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2596758(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of FR2596758A1 publication Critical patent/FR2596758A1/fr
Application granted granted Critical
Publication of FR2596758B1 publication Critical patent/FR2596758B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
FR8704705A 1986-04-04 1987-04-03 Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant Expired FR2596758B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (2)

Publication Number Publication Date
FR2596758A1 FR2596758A1 (fr) 1987-10-09
FR2596758B1 true FR2596758B1 (fr) 1988-12-02

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8704705A Expired FR2596758B1 (fr) 1986-04-04 1987-04-03 Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant

Country Status (47)

Country Link
US (1) US4879303A (enExample)
EP (1) EP0244944B1 (enExample)
JP (1) JPS62240660A (enExample)
KR (1) KR950006710B1 (enExample)
CN (1) CN1023800C (enExample)
AP (1) AP50A (enExample)
AR (1) AR242562A1 (enExample)
AT (1) ATE49752T1 (enExample)
BE (1) BE1000130A4 (enExample)
BG (1) BG60698B2 (enExample)
CA (1) CA1321393C (enExample)
CS (1) CS265237B2 (enExample)
CY (1) CY1669A (enExample)
CZ (1) CZ289095B6 (enExample)
DD (1) DD265142A5 (enExample)
DE (2) DE3710457A1 (enExample)
DK (1) DK171708B1 (enExample)
EC (1) ECSP941129A (enExample)
EG (1) EG18266A (enExample)
ES (2) ES2012803B3 (enExample)
FI (1) FI85017C (enExample)
FR (1) FR2596758B1 (enExample)
GB (2) GB8608335D0 (enExample)
GR (2) GR870525B (enExample)
HK (1) HK76092A (enExample)
HU (1) HU196962B (enExample)
IE (1) IE59457B1 (enExample)
IL (1) IL82101A (enExample)
IN (1) IN168414B (enExample)
IT (1) IT1203853B (enExample)
LU (1) LU86812A1 (enExample)
MA (1) MA20938A1 (enExample)
MX (1) MX5847A (enExample)
MY (1) MY101177A (enExample)
NL (1) NL8700791A (enExample)
NO (1) NO172181C (enExample)
NZ (1) NZ219868A (enExample)
PH (1) PH24348A (enExample)
PL (1) PL149532B1 (enExample)
PT (1) PT84611B (enExample)
SE (1) SE463457B (enExample)
SG (1) SG59692G (enExample)
SK (1) SK278435B6 (enExample)
SU (1) SU1498388A3 (enExample)
UA (1) UA6344A1 (enExample)
YU (1) YU44801B (enExample)
ZA (1) ZA872439B (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
AU3147593A (en) * 1991-11-26 1993-06-28 Sepracor, Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
MX9706957A (es) 1995-03-16 1997-11-29 Pfizer Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
TR200100062T2 (tr) 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
UA33033A (uk) * 1998-10-16 2001-02-15 Др.Редіс Леборетрис Лтд Спосіб одержання безилату амлодипіну
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
RU2142942C1 (ru) * 1999-04-28 1999-12-20 Дж. Б.Кемикалс энд Фармасьютикалс Лтд. Способ получения монобензолсульфоната 3-этил-5-метилового эфира 2-[(2-аминоэтокси)метил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5-пиридинди карбоновой кислоты
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
PT1180102E (pt) 1999-05-27 2004-08-31 Pfizer Prod Inc Pro-farmacos mutuos de amlodipina e atorvastatina
RU2161156C1 (ru) * 1999-06-01 2000-12-27 Джи.Б.Кемикалс Энд Фармасьютикалс Лтд Способ получения 3-этил-5-метиловый эфир 2-[2-(n-фталимидо)-этоксиметил]-4-(2-хлорфенил)-1,4-дигидро-6-метил-3,5- пиридиндикарбоновой кислоты
UA72768C2 (en) * 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
RU2146672C1 (ru) * 1999-10-13 2000-03-20 Др.Редди'С Лабораторис Лтд. Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2001283085A1 (en) 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
EP1309555B1 (en) * 2000-12-29 2005-07-27 Pfizer Limited Process for making amlodipine maleate
WO2002054062A2 (en) 2000-12-29 2002-07-11 Pfizer Limited Reference standards and processes for determining the purity or stability of amlodipine maleate
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
DE60116514T2 (de) 2000-12-29 2006-08-17 Pfizer Ltd., Sandwich Amlodipinhemimaleat
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
BR0116553A (pt) * 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
BR0116554A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
DE50112189D1 (de) * 2001-01-09 2007-04-26 Siegfried Generics Int Ag Salze von Amlodipin-Mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
ATE454890T1 (de) 2001-07-06 2010-01-15 Lek Pharmaceuticals Verfahren zur herstellung hochreines amlodipinbenzolsulfonat
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
AR037565A1 (es) * 2001-11-21 2004-11-17 Synthon Bv Formas de sales de amlodipina y procedimientos para prepararlas.
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003089414A1 (en) * 2002-04-13 2003-10-30 Hanlim Pharmaceutical Co., Ltd. Amlodipine nicotinate and process for the preparation thereof
ATE448799T1 (de) 2002-05-06 2009-12-15 Endocyte Inc Folatrezeptor gerichtete bildgebende konjugate
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
RU2221784C1 (ru) * 2002-07-05 2004-01-20 Марвел Лайфсайнсез Прайвит Лимитед Способ получения бензолсульфоната амлодипина
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) * 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) * 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
US7304166B2 (en) 2002-08-29 2007-12-04 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
US7279492B2 (en) 2002-09-11 2007-10-09 Hanlim Pharmaceutical Co., Ltd. S-(−)-amlodipine nicotinate and process for the preparation thereof
WO2004026834A1 (en) * 2002-09-19 2004-04-01 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
AU2002368531A1 (en) * 2002-12-30 2004-07-22 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
KR100558505B1 (ko) 2003-01-27 2006-03-07 한미약품 주식회사 안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
US20060270715A1 (en) * 2003-02-28 2006-11-30 Singh Romi B Dosage forms of amlodipine and processes for their preparation
EP2113506A3 (en) 2003-04-25 2010-02-24 Cadila Healthcare Limited Salts of clopidogrel and process for preparation
WO2004096770A1 (en) * 2003-04-25 2004-11-11 Cipla Limited Process for preparing almodipine mesylate monohydrate
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EP1626713A2 (en) * 2003-05-16 2006-02-22 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
NZ577031A (en) 2003-05-30 2010-09-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-CO inhibitors
RU2239433C1 (ru) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая вазодилатирующим, антиангинальным, гипотензивным и спазмолитическим действием, и способ ее изготовления
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005089353A2 (en) * 2004-03-16 2005-09-29 Sepracor Inc. (s)-amlodipine malate
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
WO2006044771A2 (en) * 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
AU2005302452B2 (en) * 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
US20080305158A1 (en) * 2004-12-28 2008-12-11 Ranbaxy Laboratories Limited Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
ES2303198T3 (es) * 2005-09-28 2008-08-01 Teva Pharmaceutical Industries Ltd. Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo.
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007054896A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
CN101511388B (zh) 2006-07-17 2012-10-24 特拉维夫大学拉莫特有限公司 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
JP4592818B2 (ja) * 2007-01-29 2010-12-08 ハナル バイオファーマ カンパニー リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドの酢酸塩、その製造方法、及びそれを含む薬剤学的組成物
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2009032286A2 (en) 2007-09-06 2009-03-12 Nektar Therapeutics Al, Corporation Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
KR101226669B1 (ko) * 2007-09-21 2013-01-25 한올바이오파마주식회사 Ｎ,ｎ－디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물
MX2010007281A (es) 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
RU2359672C1 (ru) * 2008-02-18 2009-06-27 Зао "Биоком" Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (en) * 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
WO2010070705A1 (ja) * 2008-12-17 2010-06-24 株式会社メドレックス アムロジピンの安定な含水経口製剤
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
JP2013520521A (ja) * 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
CA2782514A1 (en) 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
EP2539857A4 (en) 2010-02-24 2013-07-24 Univ Ramot CRYSTALLINE FORMS OF TRI MESYLATE SALT OF PERPHENAZINE GABA AND METHOD OF MANUFACTURING THEREOF
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
MY160734A (en) * 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
SMT201800571T1 (it) 2012-03-15 2019-01-11 Celgene Car Llc Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014122585A1 (en) 2013-02-08 2014-08-14 Wockhardt Limited A stable pharmaceutical composition of amlodipine and benazepril or salts thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
ES2811347T3 (es) 2015-08-14 2021-03-11 Endocyte Inc Método de formación de imágenes con un compuesto quelante
WO2017068532A1 (en) 2015-10-23 2017-04-27 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
EP3463309B1 (en) 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
ES3035030T3 (en) 2016-10-07 2025-08-28 Silvergate Pharmaceuticals Inc Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
CN112334134A (zh) 2018-04-11 2021-02-05 希沃盖特制药公司 氨氯地平制剂
EP3807892A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
WO2023285646A1 (en) 2021-07-15 2023-01-19 Adamed Pharma S.A A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
SE463457B (sv) 1990-11-26
FI85017B (fi) 1991-11-15
CY1669A (en) 1993-05-14
AP8700060A0 (en) 1987-02-01
GB2188630A (en) 1987-10-07
DK170187A (da) 1987-10-05
PT84611B (pt) 1989-11-30
AU573123B2 (en) 1988-05-26
EP0244944A3 (en) 1988-01-07
BG60698B2 (en) 1995-12-29
KR950006710B1 (ko) 1995-06-21
LU86812A1 (fr) 1987-08-12
FI85017C (fi) 1992-02-25
DE3710457A1 (de) 1987-10-08
YU44801B (en) 1991-02-28
SG59692G (en) 1992-12-04
EP0244944B1 (en) 1990-01-24
JPH037668B2 (enExample) 1991-02-04
EP0244944A2 (en) 1987-11-11
MX5847A (es) 1993-08-01
DK171708B1 (da) 1997-04-01
AR242562A1 (es) 1993-04-30
NO871408D0 (no) 1987-04-03
NZ219868A (en) 1989-02-24
ES2002599A6 (es) 1988-08-16
FR2596758A1 (fr) 1987-10-09
SE8701348D0 (sv) 1987-03-31
IE59457B1 (en) 1994-02-23
GB2188630B (en) 1990-04-04
MY101177A (en) 1991-07-31
YU58087A (en) 1988-08-31
PT84611A (en) 1987-05-01
DD265142A5 (de) 1989-02-22
NO172181B (no) 1993-03-08
SK278435B6 (en) 1997-05-07
FI871470L (fi) 1987-10-05
GB8707653D0 (en) 1987-05-07
ATE49752T1 (de) 1990-02-15
GR3000394T3 (en) 1991-06-07
CS353991A3 (en) 1992-04-15
AU7103087A (en) 1987-10-08
EG18266A (en) 1992-12-30
GR870525B (en) 1987-08-12
MA20938A1 (fr) 1987-12-31
NO871408L (no) 1987-10-05
IL82101A0 (en) 1987-10-30
CS236387A2 (en) 1989-01-12
AP50A (en) 1989-09-16
CS265237B2 (en) 1989-10-13
CN87102493A (zh) 1987-10-14
DK170187D0 (da) 1987-04-03
PH24348A (en) 1990-06-13
BE1000130A4 (fr) 1988-04-12
SE8701348L (sv) 1987-10-05
ECSP941129A (es) 1994-12-15
SU1498388A3 (ru) 1989-07-30
IL82101A (en) 1991-01-31
HUT43821A (en) 1987-12-28
JPS62240660A (ja) 1987-10-21
PL264982A1 (en) 1988-05-26
IT1203853B (it) 1989-02-23
HK76092A (en) 1992-10-09
NO172181C (no) 1993-06-16
GB8608335D0 (en) 1986-05-08
IN168414B (enExample) 1991-03-30
NL8700791A (nl) 1987-11-02
FI871470A0 (fi) 1987-04-03
US4879303A (en) 1989-11-07
PL149532B1 (en) 1990-02-28
ZA872439B (en) 1988-11-30
HU196962B (en) 1989-02-28
CN1023800C (zh) 1994-02-16
CA1321393C (en) 1993-08-17
UA6344A1 (uk) 1994-12-29
IE870869L (en) 1987-10-04
KR870009998A (ko) 1987-11-30
CZ289095B6 (cs) 2001-10-17
DE3761485D1 (de) 1990-03-01
ES2012803B3 (es) 1990-04-16
IT8719977A0 (it) 1987-04-03

Similar Documents

Publication Publication Date Title
FR2596758B1 (fr) Sels pharmaceutiques d'amlodipine ameliores et compositions pharmaceutiques les contenant
FR2582513B1 (fr) Compositions pharmaceutiques contenant de l'alfuzosine
FR2608427B1 (fr) Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant
FR2612516B1 (fr) Derives de benzoxazole et preparation les contenant
PT87492A (pt) Process for the preparation of benzo ]b" pyrrans and pyranopyridines and pharmaceutical compositions containing them
FR2586562B1 (fr) Composition pharmaceutique contenant de l'a-methylhistamine
FR2598706B1 (fr) Derives de tetrahydronaphtalene, compositions pharmaceutiques les contenant et procede de preparation
FR2466248B1 (fr) Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant
FR2626002B1 (fr) Nucleosides dideoxydidehydrocarbocycliques et composition pharmaceutique les contenant
BE892805A (fr) Cycloalcanes substitues et compositions pharmaceutiques les contenant
BE887970A (fr) Nouveaux derives d'ocytocine et compositions pharmaceutiques contenant ces derives
FR2645152B1 (fr) 3h-pteridinones-4, procedes de preparation et medicaments les contenant
FR2601875B1 (fr) Composition pharmaceutique hydrosoluble contenant de la n-acetyl-cysteine et du sorbitol
FR2567510B1 (fr) Composes d'aminophenol et compositions pharmaceutiques les contenant
PT79365A (fr) Procede de preparation de derives d'imidazoline et de compositions pharmaceutiques les contenant
PT83593A (fr) Procede de preparation de 7-acyl-benzoxazinones et leurs derives et de compositions pharmaceutiques les contenant
PT84724A (fr) Procede de preparation de benzimidazoles et imidazopyridines sulfonamides et des compositions pharmaceutiques les contenant
FR2640269B1 (fr) Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
FR2620450B1 (fr) Nouveaux sels de composes organogermaniques et medicaments les contenant
PT82364B (fr) Procede de preparation de derives du nitrofuranne et de compositions pharmaceutiques les contenant
FR2532309B1 (fr) Perfluorocycloamines et preparation d'emulsions therapeutiques contenant ces perfluorocycloamines
PT84184A (pt) Process for the preparation of 8 alpha-acylaminoergolines and of pharmaceutical compositions containing them
FR2634764B1 (fr) Heterocycles oxaza et compositions pharmaceutiques les contenant
FR2528425B1 (fr) 1,4-dihydropyridines et composition pharmaceutique les contenant
FR2609392B1 (fr) Compositions pharmaceutiques contenant des pyranoquinoleines

Legal Events

Date Code Title Description
ST Notification of lapse